NOD2基因3020insC突变与家族性胰腺癌风险？ - Suppr

Suppr

超能文献

The NOD2 3020insC Mutation and The Risk of Familial Pancreatic Cancer?

作者信息

Nej Katarzyna, Bartsch Detlef K, Sina-Frey Mercedes, Rieder Harald, Hahn Stephan A, Lubiński Jan

机构信息

Inter-University Unit of Molecular Biology, University of Szczecin and Pomeranian Medical University, Szczecin, Poland.

Department of Surgery, Philipps-University, Marburg, Germany.

出版信息

Hered Cancer Clin Pract. 2004 Jul 15;2(3):149-150. doi: 10.1186/1897-4287-2-3-149.

DOI:10.1186/1897-4287-2-3-149

PMID:20233470

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3835413/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dcc/3835413/de89ebe2f00e/1897-4287-2-3-149-1.jpg

相似文献

The NOD2 3020insC Mutation and The Risk of Familial Pancreatic Cancer?

Hered Cancer Clin Pract. 2004 Jul 15;2(3):149-150. doi: 10.1186/1897-4287-2-3-149.

NOD2 3020insC alone is not sufficient for colorectal cancer predisposition.

Cancer Res. 2004 Oct 15;64(20):7245-7. doi: 10.1158/0008-5472.CAN-04-2364.

The 3020insC NOD2 gene mutation in patients with ovarian cancer.

Ginekol Pol. 2008 Aug;79(8):544-9.

Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer.

Breast Cancer Res Treat. 2006 Jan;95(2):141-5. doi: 10.1007/s10549-005-9057-z.

The NOD2 3020insC mutation and the risk of colorectal cancer.

Cancer Res. 2004 Mar 1;64(5):1604-6. doi: 10.1158/0008-5472.can-03-3791.

The NOD2 3020insC Mutation in Women with Breast Cancer from the Bydgoszcz Region in Poland. First Results.

Hered Cancer Clin Pract. 2006 Jan 15;4(1):15-9. doi: 10.1186/1897-4287-4-1-15.

The 3020insC mutation of the NOD2/CARD15 gene in patients with periodontal disease.

Eur J Oral Sci. 2004 Aug;112(4):316-9. doi: 10.1111/j.1600-0722.2004.00137.x.

NOD2 3020insC mutation and the pathogenesis of Crohn's disease: impaired IL-1beta production points to a loss-of-function phenotype.

Neth J Med. 2005 Sep;63(8):305-8.

Pilot study on low penetrance breast and colorectal cancer predisposition markers in latvia.

Hered Cancer Clin Pract. 2006 Jan 15;4(1):48-51. doi: 10.1186/1897-4287-4-1-48.

NOD2/CARD15 mutations and the risk of reoperation in patients with Crohns disease.

Rozhl Chir. 2015 Jun;94(6):242-6.

引用本文的文献

The known genetic variants of BRCA1, BRCA2 and NOD2 in pancreatitis and pancreatic cancer risk assessment.

Sci Rep. 2025 Jan 13;15(1):1791. doi: 10.1038/s41598-025-86249-8.

Bladder cancer survival in patients with or variants.

Oncotarget. 2022 Apr 22;13:628-640. doi: 10.18632/oncotarget.28226. eCollection 2022.

NOD2 mutations and colorectal cancer - Where do we stand?

World J Gastrointest Surg. 2016 Apr 27;8(4):284-93. doi: 10.4240/wjgs.v8.i4.284.

NOD2 polymorphisms associated with cancer risk: a meta-analysis.

PLoS One. 2014 Feb 20;9(2):e89340. doi: 10.1371/journal.pone.0089340. eCollection 2014.

Risk factors and therapeutic targets in pancreatic cancer.

Front Oncol. 2013 Nov 18;3:282. doi: 10.3389/fonc.2013.00282.

German national case collection for familial pancreatic cancer (FaPaCa): ten years experience.

Fam Cancer. 2011 Jun;10(2):323-30. doi: 10.1007/s10689-010-9414-x.

[Hereditary pancreatic cancer].

Chirurg. 2008 Nov;79(11):1029-37. doi: 10.1007/s00104-008-1559-x.

Low frequency of CHEK2 mutations in familial pancreatic cancer.

Fam Cancer. 2006;5(4):305-8. doi: 10.1007/s10689-006-7850-4. Epub 2006 Jul 20.

[Prophylactic pancreas surgery].

Chirurg. 2006 Jan;77(1):25-32. doi: 10.1007/s00104-005-1113-z.

本文引用的文献

The NOD2 3020insC mutation and the risk of colorectal cancer.

Cancer Res. 2004 Mar 1;64(5):1604-6. doi: 10.1158/0008-5472.can-03-3791.

Abnormal pancreatic imaging in Crohn's disease: prevalence and clinical features.

J Gastroenterol. 2004 Jan;39(1):26-33. doi: 10.1007/s00535-003-1241-5.

Surveillance for familial pancreatic cancer.

Scand J Gastroenterol Suppl. 2003(239):94-9. doi: 10.1080/00855920310002762.

[Chronic pancreatitis as the initial presentation of Crohn's disease].

Gastroenterol Hepatol. 2003 May;26(5):300-2. doi: 10.1016/s0210-5705(03)70361-6.

Genetic abnormalities in pancreatic cancer.

Mol Cancer. 2003 Jan 7;2:7. doi: 10.1186/1476-4598-2-7.

Update of familial pancreatic cancer in Germany.

Pancreatology. 2001;1(5):510-6. doi: 10.1159/000055853.

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Nature. 2001 May 31;411(6837):603-6. doi: 10.1038/35079114.

Molecular technology and pancreatic cancer.

Br J Surg. 2000 Jul;87(7):840-53. doi: 10.1046/j.1365-2168.2000.01510.x.

Pancreatitis associated with Crohn's disease: a premalignant state for cystadenocarcinoma of pancreas?

Am J Gastroenterol. 1999 Aug;94(8):2301-2. doi: 10.1111/j.1572-0241.1999.01322.x.

Progress in cancer genetics: lessons from pancreatic cancer.

Ann Oncol. 1999;10 Suppl 4:4-8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The NOD2 3020insC Mutation and The Risk of Familial Pancreatic Cancer?

Hered Cancer Clin Pract. 2004 Jul 15;2(3):149-150. doi: 10.1186/1897-4287-2-3-149.

NOD2 3020insC alone is not sufficient for colorectal cancer predisposition.

Cancer Res. 2004 Oct 15;64(20):7245-7. doi: 10.1158/0008-5472.CAN-04-2364.

The 3020insC NOD2 gene mutation in patients with ovarian cancer.

Ginekol Pol. 2008 Aug;79(8):544-9.

Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer.

Breast Cancer Res Treat. 2006 Jan;95(2):141-5. doi: 10.1007/s10549-005-9057-z.

The NOD2 3020insC mutation and the risk of colorectal cancer.

Cancer Res. 2004 Mar 1;64(5):1604-6. doi: 10.1158/0008-5472.can-03-3791.

The NOD2 3020insC Mutation in Women with Breast Cancer from the Bydgoszcz Region in Poland. First Results.

Hered Cancer Clin Pract. 2006 Jan 15;4(1):15-9. doi: 10.1186/1897-4287-4-1-15.

The 3020insC mutation of the NOD2/CARD15 gene in patients with periodontal disease.

Eur J Oral Sci. 2004 Aug;112(4):316-9. doi: 10.1111/j.1600-0722.2004.00137.x.

NOD2 3020insC mutation and the pathogenesis of Crohn's disease: impaired IL-1beta production points to a loss-of-function phenotype.

Neth J Med. 2005 Sep;63(8):305-8.

Pilot study on low penetrance breast and colorectal cancer predisposition markers in latvia.

Hered Cancer Clin Pract. 2006 Jan 15;4(1):48-51. doi: 10.1186/1897-4287-4-1-48.

NOD2/CARD15 mutations and the risk of reoperation in patients with Crohns disease.

Rozhl Chir. 2015 Jun;94(6):242-6.

引用本文的文献

The known genetic variants of BRCA1, BRCA2 and NOD2 in pancreatitis and pancreatic cancer risk assessment.

Sci Rep. 2025 Jan 13;15(1):1791. doi: 10.1038/s41598-025-86249-8.

Bladder cancer survival in patients with or variants.

Oncotarget. 2022 Apr 22;13:628-640. doi: 10.18632/oncotarget.28226. eCollection 2022.

NOD2 mutations and colorectal cancer - Where do we stand?

World J Gastrointest Surg. 2016 Apr 27;8(4):284-93. doi: 10.4240/wjgs.v8.i4.284.

NOD2 polymorphisms associated with cancer risk: a meta-analysis.

PLoS One. 2014 Feb 20;9(2):e89340. doi: 10.1371/journal.pone.0089340. eCollection 2014.

Risk factors and therapeutic targets in pancreatic cancer.

Front Oncol. 2013 Nov 18;3:282. doi: 10.3389/fonc.2013.00282.

German national case collection for familial pancreatic cancer (FaPaCa): ten years experience.

Fam Cancer. 2011 Jun;10(2):323-30. doi: 10.1007/s10689-010-9414-x.

[Hereditary pancreatic cancer].

Chirurg. 2008 Nov;79(11):1029-37. doi: 10.1007/s00104-008-1559-x.

Low frequency of CHEK2 mutations in familial pancreatic cancer.

Fam Cancer. 2006;5(4):305-8. doi: 10.1007/s10689-006-7850-4. Epub 2006 Jul 20.

[Prophylactic pancreas surgery].

Chirurg. 2006 Jan;77(1):25-32. doi: 10.1007/s00104-005-1113-z.

本文引用的文献

The NOD2 3020insC mutation and the risk of colorectal cancer.

Cancer Res. 2004 Mar 1;64(5):1604-6. doi: 10.1158/0008-5472.can-03-3791.

Abnormal pancreatic imaging in Crohn's disease: prevalence and clinical features.

J Gastroenterol. 2004 Jan;39(1):26-33. doi: 10.1007/s00535-003-1241-5.

Surveillance for familial pancreatic cancer.

Scand J Gastroenterol Suppl. 2003(239):94-9. doi: 10.1080/00855920310002762.

[Chronic pancreatitis as the initial presentation of Crohn's disease].

Gastroenterol Hepatol. 2003 May;26(5):300-2. doi: 10.1016/s0210-5705(03)70361-6.

Genetic abnormalities in pancreatic cancer.

Mol Cancer. 2003 Jan 7;2:7. doi: 10.1186/1476-4598-2-7.

Update of familial pancreatic cancer in Germany.

Pancreatology. 2001;1(5):510-6. doi: 10.1159/000055853.

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Nature. 2001 May 31;411(6837):603-6. doi: 10.1038/35079114.

Molecular technology and pancreatic cancer.

Br J Surg. 2000 Jul;87(7):840-53. doi: 10.1046/j.1365-2168.2000.01510.x.

Pancreatitis associated with Crohn's disease: a premalignant state for cystadenocarcinoma of pancreas?

Am J Gastroenterol. 1999 Aug;94(8):2301-2. doi: 10.1111/j.1572-0241.1999.01322.x.

Progress in cancer genetics: lessons from pancreatic cancer.

Ann Oncol. 1999;10 Suppl 4:4-8.